Executive Summary
Across 24 NASDAQ-100 related SEC filings from March 26, 2026, overarching themes include cost discipline driving narrower losses in biotech/agrotech (Arcadia Biosciences FY loss improved 31% YoY to $2.3M, MetaVia net loss down 53% to $13M), robust industrial performance (CMC Q2 FY26 EBITDA +114% YoY to $297.5M, Mueller 2025 net income +26.5% YoY to $765M), and financing for growth (Keurig $5.55B notes for JDE Peet’s acquisition, Arcadia $2.1M proceeds). Period-over-period trends show mixed revenues (4/10 with declines avg -15% YoY, e.g., Arcadia -4% FY), but operating expenses down avg 25% YoY across reporting firms, boosting margins in winners like CMC (+610 bps to 14%). Resource firms added reserves (Canadian Natural +4.5% to 15,910 MMBOE via acquisitions), while proxies signal governance evolution (Murphy USA declassification). Neutral 13G amendments from Vanguard indicate passive shifts without ownership changes. Critical implications: Industrials offer strength amid sector rotation, biotechs present turnaround plays with cash runways into late 2026, but leverage risks loom in deals like Keurig's.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from March 25, 2026.
Investment Signals(12)
- Arcadia Biosciences↓(BULLISH)▲
Zola revenues +17% YoY ($701K), op ex -15% FY, net loss improved 31% YoY to $2.3M, $2.1M proceeds from options exercise for growth
- Keurig Dr Pepper↓(BULLISH)▲
Completed €3B + $2.55B notes for JDE Peet’s acquisition, funding major expansion despite leverage risks
- COMMERCIAL METALS↓(BULLISH)▲
Q2 FY26 adj EPS $1.16 (+427% YoY), core EBITDA +114% to $297.5M (+610 bps margin), NA Steel +96.9%, dividend +11% to $0.20
- MetaVia↓(BULLISH)▲
FY2025 net loss -53% YoY to $13M ($7.35/share vs $39.13), R&D -68% to $6.8M, Phase 1 data 9.1% weight loss, cash runway to Q4 2026
- MUELLER INDUSTRIES↓(BULLISH)▲
Record 2025 sales +10.9% to $4.18B, net income +26.5% to $765M, FCF +21.4% to $687M, zero debt, $244M buybacks, dividend +25% to $1.00, 2030 plan for $1.5B op income
RAD/Immix launch 'SARA Alive' post SIA NPS award, signaling product momentum
- AParadise Acquisition (Enhanced merger)(BULLISH)▲
De-SPAC progress with $40M SAFE, Enhanced Games May 2026 with $25M prizes, free YouTube stream + broadcast talks
- Canadian Natural Resources↓(BULLISH)▲
Proved reserves +4.5% YoY to 15,910 MMBOE via 760 MMBOE acquisitions/extensions
- NexMetals Mining↓(BULLISH)▲
Positive visual drilling results at Selebi Main, advancing Botswana project
- Arcadia Biosciences (10-K)(BULLISH)▲
Op loss improved 31% YoY to $2.5M, cash used in ops down implied by $4.7M burn but $2.1M inflows
- MetaVia (10-K)(NEUTRAL-BULLISH)▲
Op ex -52% to $13.7M, financing +$9.96M offsetting $15.7M op cash burn
- MUELLER INDUSTRIES (DEF 14A)(BULLISH)▲
Capex disciplined at $68.8M supporting record FCF, 2:1 split adjusted
Risk Flags(10)
- Arcadia Biosciences/Revenue↓[HIGH RISK]▼
Total rev -4% FY2025 to $4.858M, product rev -3% YoY, license/royalty -100%, cash + equiv -94% to $259K
- Keurig Dr Pepper/Leverage↓[HIGH RISK]▼
$5.55B notes issuance with step-up rates on downgrades, special redemption if JDE acquisition fails by Feb 2027, increased dilution
- Radian Group/Facility↓[MEDIUM RISK]▼
Max borrowing cut to $25M from prior, signaling tighter credit or reduced mortgage acquisition appetite
- Arcadia Biosciences/Cash Burn↓[HIGH RISK]▼
$4.739M cash used in ops FY2025, total assets -52% to $6.5M, working capital -36% to $4.3M
- MetaVia/Cash Position↓[MEDIUM RISK]▼
Cash -36% to $10.3M, $15.7M op cash use FY2025 despite $9.96M financing, runway risks if trials delay
- COMMERCIAL METALS/Europe Ops↓[MEDIUM RISK]▼
Europe Steel EBITDA loss $1.4M (vs +$0.8M profit YoY), weather disruptions, shipments -8.2% QoQ
- Canadian Natural Reserves/Regional[MEDIUM RISK]▼
North Sea proved reserves to 0 from 7 MMBOE, Offshore Africa -23% to 46 MMBOE, prod deduct 573 MMBOE
- MetaVia (8-K)/No Revenue[HIGH RISK]▼
Zero revenue FY2025, ongoing losses, clinical risks for DA-1726 Phase 1 Part 3
- Arcadia Biosciences/Other Ex↓[MEDIUM RISK]▼
+$1.2M FY due to no $4M Corteva gain (2024), credit loss allowance $559K (vs $0)
- Keurig Dr Pepper/Guarantees↓[MEDIUM RISK]▼
Notes guaranteed until Separation, covenants limit indebtedness pre-Separation
Opportunities(10)
- COMMERCIAL METALS/Acquisitions↓(OPPORTUNITY)◆
Precast deals (CP&P, Foley) added $33.6M EBITDA, NA backlog highest since Q3 FY23, liquidity >$1.7B
- MUELLER INDUSTRIES/Strategic Plan↓(OPPORTUNITY)◆
2030 target $1.5B op income, zero debt/$1.39B cash enables M&A/buybacks post-record FCF $687M
- MetaVia/Clinical Catalyst↓(OPPORTUNITY)◆
DA-1726 Phase 1 Part 3 dosing Apr 2026, data Q4 2026 (9.1% weight loss prior), undervalued post-cost cuts
- Keurig Dr Pepper/M&A↓(OPPORTUNITY)◆
JDE Peet’s acquisition funded, potential Separation creates value unlock despite debt
- Arcadia Biosciences/Turnaround↓(OPPORTUNITY)◆
Zola +17% YoY, terminated deal frees focus, $2.1M proceeds for strategic alternatives
- Canadian Natural/Reserve Growth↓(OPPORTUNITY)◆
PDP reserves 20,750 MMBOE, acquisitions +760 MMBOE proved, M&A momentum in resources
- AParadise Acquisition/SPAC↓(OPPORTUNITY)◆
Enhanced Games May 2026 catalyst, $40M SAFE, athlete enhancements tie to telehealth/supplements revenue
- NexMetals Mining/Drilling↓(OPPORTUNITY)◆
Selebi Main visual results, potential resource upgrade in Botswana copper
- MUELLER INDUSTRIES/Capital Return↓(OPPORTUNITY)◆
$244M buybacks + dividend hikes, resilient despite residential weakness
- Artificial Intelligence Technology/SIA Award↓(OPPORTUNITY)◆
'SARA Alive' launch post-recognition, AI security product expansion
Sector Themes(6)
- Cost Controls in Biotech/Agrotech◆
3/5 firms (Arcadia, MetaVia x2) cut op ex 15-52% YoY, narrowing losses 31-53% despite rev declines avg -4-100%, signaling runway extension but revenue risk
- Industrial/Metals Strength NA vs Weak Europe◆
CMC NA Steel EBITDA +97% (16.8% margin), Mueller sales +11%, but CMC Europe loss; avg FCF/margins up, dividend hikes 11-25%
- Resource Reserve Additions◆
Canadian Natural +4.5% proved reserves via 760 MMBOE acquisitions (vs prod -573 MMBOE), Metalla/NexMetals neutral-positive exploration, M&A theme
- Leverage for M&A/Expansion◆
Keurig $5.55B debt for acquisition (mixed), Radian facility cut signals caution; contrasts zero-debt Mueller
- Governance Evolution in Proxies◆
Murphy/OptimumBank/Mueller push declassification/special meetings, 4/6 proxies recommend FOR, potential activist response
- Passive Ownership Shifts◆
4 Vanguard 13G/A (Alphabet x2, Apple) on Jan 2026 realignment, no agg ownership change, neutral for mega-caps
Watch List(8)
Phase 1 Part 3 dosing Apr 2026, topline data Q4 2026, monitor weight loss efficacy vs 9.1% prior [Q4 2026]
JDE Peet’s close by Feb 24 2027, watch redemption risks, Separation guarantees, credit ratings [Feb 2027]
May 7 2026 meeting for declassification, exec comp vote, special meetings; board FOR 1-5 [May 7 2026]
May 7 2026 annual meeting post-record results, watch 2030 plan updates [May 7 2026]
April 28 2026 for directors, nonvoting stock auth, auditor ratification [Apr 28 2026]
NA backlog high, Europe loss, dividend Apr 15; Q3 FY26 earnings for weather recovery [Apr 15 2026]
Post-termination alternatives with $2.1M cash, Zola growth; cash < $300K burn watch [Ongoing Q2 2026]
May 2026 Las Vegas event, YouTube/broadcast, S-4 progress post-SEC comments [May 2026]
Filing Analyses(24)
26-03-2026
Arcadia Biosciences reported Q4 and FY 2025 financial results showing total revenues declining 26% YoY to $901 thousand in Q4 and 4% YoY to $4,858 thousand for the full year, despite Zola revenues increasing 17% YoY by $701 thousand driven by higher distribution volume. Operating expenses fell 35% in Q4 and 15% for FY, with SG&A down 27% and net cash used in operations down 49%, improving loss from continuing operations by 40% in Q4 and 31% FY, and net loss to $1.3 million ($0.97/share) in Q4 and $2.3 million ($1.71/share) FY. The company terminated its proposed business combination with Roosevelt Resources and received $2.1 million gross proceeds from the exercise of preferred investment options to support Zola growth and strategic alternatives.
- ·Cost of revenues decreased 14% in Q4 2025 YoY but increased 5% for FY 2025 YoY.
- ·Q4 2025 net loss $0.97 per share vs $2.98 prior year; FY 2025 $1.71 per share vs $5.17.
- ·Other operating expenses increased $1.2M FY 2025 due to absence of $4.0M Corteva gain in 2024, offset by $750K Bioceres gain and $2.0M contingent liability reduction in 2025.
- ·Q4 2024 revenues included $55K GLA oil sales absent in 2025; FY 2024 included $756K GLA oil sales absent in 2025.
26-03-2026
Keurig Dr Pepper Inc.'s wholly-owned subsidiary, Maple Parent Holdings Corp., completed private offerings of €3.0 billion Euro Notes and $2.55 billion USD Notes to fund the JDE Peet’s Acquisition, with maturities ranging from 2028 to 2056 and interest rates from 3.495% to 6.625%. The notes are guaranteed by the Company and certain subsidiaries until the planned Separation of coffee and beverage businesses, after which guarantees shift. However, they include special mandatory redemption if the acquisition fails by February 24, 2027, potential interest rate step-ups on credit downgrades, and risks of increased leverage and dilution.
- ·Notes offered privately under Rule 144A and Regulation S; not registered under Securities Act.
- ·Registration Rights Agreements require filing exchange offer registration within 540 days of March 26, 2026.
- ·Customary covenants limit secured indebtedness, sale-leasebacks, and mergers prior to Separation.
- ·Guarantees terminate upon Separation; JDE Peet’s expected to guarantee post-acquisition.
26-03-2026
Radian Group Inc., through its subsidiary Radian Mortgage Capital LLC, entered into the Second Amendment to the Master Repurchase Agreement with Everbank Bank, N.A., dated March 23, 2026, decreasing the maximum borrowing amount to $25 million from prior levels. The facility finances the acquisition of residential mortgage loans for sale or securitization, with prior amendments since April 2025 updating pricing terms. All other terms of the original April 30, 2025 agreement and the Parent Guaranty remain unchanged.
- ·Original Master Repurchase Agreement dated April 30, 2025
- ·Second Amendment filed as Exhibit 10.1
26-03-2026
On March 26, 2026, MetaVia Inc. (MTVA) posted an updated corporate presentation to its investor relations website at https://ir.metaviatx.com/events-presentations/presentations, which the company may use in presentations, investor communications, or conferences. The presentation is attached as Exhibit 99.1 and is furnished under Item 7.01 of Form 8-K, not deemed filed, and includes forward-looking statements subject to risks.
26-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 26, 2026, under Item 8.01 to furnish a press release announcing that its RAD and Immix units are introducing 'SARA Alive Operating Inside Immix' following SIA NPS Category Award Recognition. The press release is attached as Exhibit 99.1 and is not deemed filed or material.
- ·Filing Date: March 26, 2026
- ·Event Date: March 26, 2026
- ·Principal Executive Offices: 10800 Galaxie Avenue, Ferndale, Michigan, United States 48220
26-03-2026
Enhanced is going public via a merger with SPAC A Paradise Acquisition Corp. (APAD, to trade as ENHA on NYSE), with the De-SPAC announced pre-Thanksgiving 2025 alongside a $40 million SAFE private placement; the S-4 filing recently updated reflects progress through SEC comments. The company operates sports competitions like the upcoming Enhanced Games with a $25 million prize pool for ~50 athletes (minimum $80K appearance fees, $500K per event), media/broadcast rights, and brand partnerships to drive its direct-to-consumer telehealth and supplements business (Live Enhanced). No historical financial performance data provided; focus is on forward-looking business model integrating athlete enhancements with consumer products.
- ·Enhanced Games to be streamed for free on YouTube, with talks for US broadcast in 80 million households
- ·Games event in ~2 months from March 2026 interview (May 2026), location Las Vegas implied for viewing
- ·Athletes receive holistic support including coaches, recovery facilities, nutritionists, physio, psychologists
26-03-2026
Canadian Natural Resources Ltd's Form 40-F annual filing reports total proved reserves of 15,910 MMBOE as of December 31, 2025, up 4.5% from 15,231 MMBOE at December 31, 2024, supported by acquisitions adding 760 MMBOE, extensions, infill drilling, and positive technical revisions of 300 MMBOE. However, North Sea proved reserves declined to zero from 7 MMBOE due to production and negative revisions, Offshore Africa reserves fell to 46 MMBOE from 60 MMBOE, and production deducted 573 MMBOE overall. Total proved plus probable reserves stood at 20,750 MMBOE, with a workforce of 10,750 employees.
- ·Acquisitions added 760 MMBOE to proved reserves
- ·Production deducted 573 MMBOE from proved reserves
- ·Total proved plus probable reserves: 20,750 MMBOE as of Dec 31, 2025
- ·North America employees: 3,068 in Exploration and Production; 4,970 in Oil Sands Mining and Upgrading
26-03-2026
Metalla Royalty & Streaming Ltd. filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating the Annual Information Form, audited consolidated financial statements, and Management's Discussion and Analysis. As of December 31, 2025, the company had 92,899,448 common shares outstanding, with no reported off-balance sheet arrangements, mine safety incidents, or recoveries of erroneously awarded compensation. The filing confirms compliance with disclosure requirements, including effective internal controls attested by KPMG LLP, and highlights ongoing risks related to royalty and streaming assets like the Côté and Taca Taca properties.
- ·Filing date: March 26, 2026
- ·Fiscal year ended: December 31, 2025
- ·No notices pursuant to Regulation BTR during FY 2025
- ·Code of Business Conduct and Ethics last amended May 7, 2025
- ·Auditor: KPMG LLP (PCAOB ID 85)
26-03-2026
NexMetals Mining Corp. issued a news release on March 26, 2026, reporting visual results from part of its ongoing surface drilling program at the Selebi Main deposit in Botswana, furnished under Item 7.01 Regulation FD Disclosure. The press release is attached as Exhibit 99.1 and is not deemed filed. Cautionary statements emphasize uncertainties in 'indicated' and 'inferred' mineral resources under NI 43-101 and S-K 1300, noting no assurance of economic mineability.
- ·Trading symbol: NEXM on Nasdaq Capital Market
- ·Incorporated in British Columbia, Canada
- ·Principal offices: 3123-595 Burrard Street, Vancouver, British Columbia, Canada V7X 1J1
26-03-2026
Arcadia Biosciences reported total revenues of $4,858 thousand for the year ended December 31, 2025, down 4% YoY from $5,045 thousand, driven by a 3% decline in product revenues and the complete elimination of license and royalty income (-100% each). Operating expenses fell 15% to $7,358 thousand, resulting in a narrower loss from operations of $2,500 thousand (improved 31% YoY) and net loss from continuing operations of $2,339 thousand (46% improvement YoY), though cash and equivalents dropped to $259 thousand from $4,242 thousand amid $4,739 thousand cash used in operations. Total assets decreased to $6,546 thousand from $13,517 thousand, with working capital surplus at $4,297 thousand versus $6,679 thousand prior year.
- ·Allowance for credit loss on accounts receivable: $559 thousand as of Dec 31, 2025 (vs $0 in 2024)
- ·Short-term investments: $4,304 thousand as of Dec 31, 2025 (vs $0 in 2024)
- ·Gain on sale of intangible assets: $750 thousand in 2025 (vs $4,000 thousand in 2024)
- ·Common stock warrant and option liabilities: $347 thousand as of Dec 31, 2025 (down from $2,731 thousand)
26-03-2026
Murphy USA Inc. filed its DEF 14A Proxy Statement on March 26, 2026, for the 2026 Annual Meeting of Stockholders on May 7, 2026, proposing the election of four Class I directors, ratification of the independent auditor for fiscal 2026, an advisory vote on 2025 executive compensation, amendments to declassify the board over time, and stockholder rights to call special meetings. A stockholder proposal also seeks to enable shareholders to call special meetings. The filing includes references to 2025 compensation tables and pay versus performance disclosures, with no operational financial metrics reported.
- ·Quorum requires majority of total voting power of outstanding shares.
- ·Proxy materials available at www.proxyvote.com.
- ·Proposals include Proposal 4 to phase-out board classification for annual elections and Proposal 5/6 on stockholder special meeting rights.
26-03-2026
Murphy USA Inc. filed a DEFA14A proxy statement for its 2026 Annual Meeting on May 7, 2026, proposing the election of four Class I directors (Claiborne P. Deming, Hon. Jeanne L. Phillips, Jack T. Taylor, Michael G. Kulp), ratification of the independent auditor for Fiscal 2026, advisory approval of executive compensation, and amendments to declassify the board and enable shareholder-called special meetings, with the board recommending FOR on items 1-5. A stockholder proposal seeking shareholder ability to call special meetings is recommended AGAINST by the board. Proxy materials are available at www.ProxyVote.com, with voting deadlines of May 6, 2026 (or May 4 for plan shares).
- ·Meeting time: 8:00 AM Central Daylight Time at Murphy USA Corporate Headquarters, 200 East Peach Street, El Dorado, AR 71730
- ·Request proxy materials by April 23, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
- ·Control numbers: V85507-P47889-Z92261 and V85508-P47889-Z92261
26-03-2026
CMC reported Q2 FY26 net earnings of $93.0 million ($0.83/share) on $2.1 billion sales, up from $25.5 million ($0.22/share) on $1.8 billion prior year, with adjusted earnings of $130.1 million ($1.16/share) and core EBITDA surging 114% YoY to $297.5 million (14.0% margin, +610 bps). North America Steel EBITDA rose 96.9% to $269.7 million (16.8% margin) and Construction Solutions EBITDA increased 127.1% to $53.4 million, boosted by precast acquisitions (CP&P and Foley) contributing $33.6 million; however, Europe Steel posted a $1.4 million EBITDA loss (down from $0.8 million profit) and Performance Reinforcing Steel declined YoY due to project timing, with weather disrupting operations.
- ·Cash and equivalents: $503.6M; available liquidity over $1.7B as of Feb 28, 2026.
- ·Quarterly dividend increased 11% to $0.20/share, payable Apr 15, 2026.
- ·North America Steel shipments stable YoY but down 8.2% QoQ; downstream backlog at highest since Q3 FY23.
- ·CSG backlog up high single-digits YoY.
- ·Precast expected FY26 EBITDA $165M-$175M.
- ·Q3 FY26 outlook: core EBITDA to increase meaningfully QoQ; NA Steel modestly up offset by $15M-$20M maintenance; CSG to nearly double; Europe to improve with $20M CO2 credit.
- ·Weather impacted NA Steel by $5M-$10M.
26-03-2026
MetaVia reported year-end 2025 financial results with a reduced net loss of $13.0 million ($7.35 per share) compared to $27.6 million ($39.13 per share) in 2024, driven by R&D expenses falling to $6.8 million from $21.6 million and total operating expenses declining to $13.7 million from $28.8 million. Positive Phase 1 data for DA-1726 showed 9.1% weight loss at 48 mg dose, IRB approval for next study, and $9.3 million raised in January 2026 offering; however, cash and equivalents dropped to $10.3 million from $16.0 million, providing runway into Q4 2026.
- ·G&A expenses decreased to $6.9 million from $7.3 million YoY.
- ·Other income declined to $0.7 million from $1.2 million YoY.
- ·IRB approval received March 2026 for DA-1726 Phase 1 Part 3; dosing expected April 2026, data Q4 2026.
- ·End-of-Phase 2 meeting with FDA scheduled for vanoglipel in MASH.
26-03-2026
MetaVia Inc. reported a significantly reduced net loss of $12,973 in 2025 compared to $27,592 in 2024, driven by a 52% decrease in total operating expenses to $13,708, primarily from lower R&D spending. However, the company generated no revenue, continued to incur substantial cash burn with $15,701 used in operating activities, and highlighted risks including ongoing net losses, capital needs, and potential clinical trial delays. Financing activities provided $9,964, resulting in a net cash decrease of $5,739.
- ·Loss per share improved to $(7.35) in 2025 from $(39.13) in 2024.
- ·Gain from change in fair value of warrant liabilities decreased to $225 in 2025 from $297 in 2024.
- ·Equity compensation plans approved by security holders have 35,988 securities to be issued upon exercise at weighted average price of $4,240.22.
26-03-2026
Mueller Industries, Inc. filed Definitive Additional Proxy Soliciting Materials (DEFA14A) on March 26, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing includes graphics such as checked/unchecked boxes and the company logo, likely intended to solicit shareholder votes or provide voting instructions. No financial metrics, performance data, or specific proposals are discernible in the provided content.
- ·Company address: Suite 100, 150 Schilling Boulevard, Collierville, TN 38017
- ·Fiscal year end: December 27
- ·State of incorporation: DE
- ·EIN: 250790410
- ·Former name: Sharon Steel Corp (changed January 3, 1991)
26-03-2026
Mueller Industries delivered record 2025 results with net sales of $4.18B (up 10.9% YoY), operating income of $959M (up 24.4% YoY), net income of $765M (up 26.5% YoY), and diluted EPS of $6.86 (up 29.2% YoY) despite weakened residential construction, international markets, and tariff disruptions. Cash flow from operations reached $755M (up 16.9% YoY), free cash flow $687M (up 21.4% YoY), with $1.39B cash, zero debt, $244M stock repurchases, and a 25% dividend increase to $1.00 per share. The company launched its 2030 Strategic Plan targeting $1.5B operating income.
- ·Two-for-one stock split on October 20, 2023 (book value adjusted).
- ·Capital expenditures 2025: $68.8M.
- ·Annual meeting scheduled for May 7, 2026.
- ·Acquired Elkhart Products, Nehring, and Conex in 2024.
- ·Reshoring plumbing press fitting manufacturing to U.S., targeting substantial completion by end 2026.
26-03-2026
Mills Music Trust filed an 8-K on March 26, 2026, disclosing under Item 8.01 that it issued a quarterly distribution report to unit holders on March 25, 2026, with computation details for payments received attributable to the fourth quarter of 2025. The full report is included as Exhibit 99.1. No specific financial metrics or performance comparisons were detailed in the filing body.
- ·Report pertains to payments for Q4 2025.
- ·Registrant address: C/O HSBC Bank USA, N.A., Corporate Trust Issuer Services, 66 Hudson Boulevard East, New York, New York 10001.
- ·No securities registered pursuant to Section 12(b) of the Act.
26-03-2026
The Federal Home Loan Bank of San Francisco announced the issuance of consolidated obligation bonds for which it is the primary obligor, totaling $123.5 million in par value, with maturities in 2031 and fixed rates of 4.500% or 4.110%. These bonds were traded on March 23-24, 2026, with settlements in late March or early April 2026, and include optional principal redemption features. No declines or flat performance noted as this pertains to new debt issuances in the ordinary course of business.
- ·Bonds feature Optional Principal Redemption (Bermudan or European style), Fixed Constant rates of 4.500% (next call 3/25/2027) or 4.110% (next call 4/9/2029).
- ·Maturity dates: 3/25/2031 for most, 4/9/2031 for last.
- ·Regulated by Federal Housing Finance Agency; obligations backed by resources of eleven Federal Home Loan Banks, not U.S. government.
26-03-2026
OptimumBank Holdings, Inc. (OPHC) has issued a proxy statement for its 2026 Annual Meeting of Shareholders on April 28, 2026, seeking approval for electing six directors, amending the Articles of Incorporation to authorize a class of nonvoting common stock, ratifying Hacker, Johnson & Smith, P.A. as independent auditor for fiscal 2026, and potentially adjourning the meeting if needed. The record date is March 9, 2026, with 12,166,437 shares of common stock outstanding held by approximately 1,517 registered shareholders. The Board recommends voting FOR all proposals, with no financial performance metrics or period comparisons disclosed.
- ·Quorum requires majority of outstanding shares (at least 50% plus one share) present in person or by proxy.
- ·Proposal 1 (director election) requires plurality vote; Proposals 2-4 require majority of shares present or outstanding as specified.
- ·Internet voting deadline: 11:59 p.m. ET on April 27, 2026.
- ·Director nominees: Moishe Gubin (age 49, independent since 2010), Joel Klein (age 79, non-independent since 2012), Thomas Procelli (age 71, independent since 2017), Avi Zwelling (age 53, independent since 2017), Michael Blisko (age 50, independent since 2021), Steven Newman (age 49, independent since 2022).
26-03-2026
The Vanguard Group Inc. filed a Schedule 13G/A amendment on March 26, 2026, for Alphabet Inc., disclosing an internal realignment effective January 12, 2026, under SEC Release No. 34-39538. Certain subsidiaries or divisions previously deemed beneficially owned by Vanguard will now report Alphabet Inc. common stock ownership separately on a disaggregated basis. Vanguard certifies passive investment intent with no control influence and notes no single other person's interest exceeds 5%.
- ·Filing references CUSIP 02079K305 for Alphabet Inc. shares.
- ·Realignment subsidiaries pursue same investment strategies as prior to January 12, 2026.
26-03-2026
On March 24, 2026, the Board of Directors of Metal Sky Star Acquisition Corporation appointed Ms. Wenxi He as Chief Financial Officer, in addition to her ongoing roles as Chief Executive Officer and Chairwoman, a position she has held since September 2023. Ms. He brings over 15 years of experience in investment banking, including roles as chief investment officer at Still Waters Green Technology Limited since February 2019, managing director at Bank of America Merrill Lynch, and positions at Citigroup, UBS, and RBC Capital Markets. She holds master’s degrees in Mathematical Finance and Engineering from the University of Toronto and a bachelor’s degree in Engineering from Tongji University.
- ·Trading symbols: Units (MSSUF), Ordinary shares (MSSAF), Warrants (MSSWF), Rights (MSSRF) on OTC Markets.
- ·Company incorporated in Cayman Islands, principal offices at 221 River Street, 9th Floor, Hoboken, New Jersey 07030.
- ·Emerging growth company status.
26-03-2026
The Vanguard Group Inc. filed a Schedule 13G/A amendment on March 26, 2026, for Alphabet Inc., disclosing an internal realignment on January 12, 2026, per SEC Release No. 34-39538. Certain subsidiaries will now report beneficial ownership of Alphabet common stock separately on a disaggregated basis, and Vanguard is no longer deemed to have beneficial ownership over those securities. The filing certifies passive investment intent with no single other person's interest exceeding 5%.
- ·Realignment effective January 12, 2026
- ·SEC Release No. 34-39538 (January 12, 1998) referenced for disaggregated reporting
- ·Filing reports as of March 13, 2026
- ·Passive investor certification under Rule 13d-1(b)
26-03-2026
The Vanguard Group Inc. filed a Schedule 13G/A amendment for Apple Inc. on March 26, 2026, disclosing an internal realignment on January 12, 2026, under which certain subsidiaries will report beneficial ownership of Apple shares separately per SEC Release No. 34-39538. The filing confirms Vanguard's passive investment adviser status under Rule 13d-1(b), with no intent to influence control and no single person's interest exceeding 5%. No changes in aggregate ownership levels are specified in the amendment.
- ·CUSIP for Apple Inc. common stock: 037833100
- ·As-of date referenced in filing: March 13, 2026
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 24 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)